Clinical Experience with Gefitinib in Indian Patients

Parikh, Purvish; Chang, Alex Y.; Nag, Shona; Digumarti, Raghunadharao; Bhattacharyya, Gouri Shankar; Doval, Dinesh Chandra; Babu, Govind; Chacko, Raju Titus; Advani, Suresh H.; Ranade, Anantbhushan; Aggarwal, Sandeep; Jagannathan, Ram; Hargreaves, Laura; Thatcher, Nick

doi:10.1097/jto.0b013e318168f794

Cited by 26 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fine tuning of the dose, co-prescription medication, extension of treatment schedule, and change to second-line therapy at the right time are part of the mid-course correction strategy that often do not get the importance they deserve. [34][35][36] …”

Section: Mid-course Correctionmentioning

confidence: 98%

Optimizing patient outcome: Of equal importance in the palliative setting

Parikh¹,

Narayanan

Bhattacharyya

2012

Indian J Cancer

View full text Add to dashboard Cite

Section: Mid-course Correctionmentioning

confidence: 98%

Optimizing patient outcome: Of equal importance in the palliative setting

Parikh¹,

Narayanan

Bhattacharyya

2012

Indian J Cancer

View full text Add to dashboard Cite

“…In a retrospective ad hoc analysis of 77 Indian patients included in the ISEL study, the median survival was observed to be 6.4 months with gefitinib and 5.1 months with placebo. The response rates were also better with gefitinib (14 vs. 0%) [32] .…”

Section: Unselected Populationmentioning

confidence: 66%

“…Parikh et al [32] analyzed 77 Indian patients enrolled in the ISEL study. The median survival and objective response rates in Indian patients were better with gefitinib compared to placebo (6.4 vs. 5.1 months; 14 vs. 0%).…”

Section: Experience From Indiamentioning

confidence: 99%

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

Malik

Jain²,

Kumar³

2016

Oncology

View full text Add to dashboard Cite

The advent of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has led to a paradigm shift in the management of advanced adenocarcinoma of the lung. The key to success of these therapies lies in the precise identification of their molecular targets, i.e. sensitizing EGFR mutations. The variations in the prevalence of these mutations among different ethnicities necessitate regional studies for a better understanding of the molecular epidemiology of the disease and clinical decision-making. This is even more relevant for countries like India where genetic heterogeneity is a rule. Here, we make an attempt to review the epidemiology of EGFR mutations in India versus other Asian countries and the West. We also review the clinical experience with EGFR TKIs and suggest the way forward in a resource-limited setting.

show abstract

“…[26] Indian Study One retrospective analysis has found median survival of 6.4 months and response rates of 14% to geftinib in refractory advanced NSCLC in India. [27] …”

Section: Geftinib In Asian Populationsmentioning

confidence: 97%

Geftinib

Gupta

Raina

2010

J Can Res Ther

View full text Add to dashboard Cite

Gefitinib is an orally active, highly selective, reversible inhibitor of the tyrosine kinase domain associated with the epidermal growth factor receptor (EGFR). EGFR gene mutations, never smoking status, Asian origin and adenocarcinoma histology are associated with good clinical responses to geftinib. Geftinib has generally been tried in the setting of chemotherapy refractory disease in patients who have failed at least one line of therapy. Trials are exploring use of geftinib as first line therapy in patients harboring EGFR mutations and also in the elderly. The most exciting feature of geftinib use is its potential for Lazarus responses in patients with poor performance status. Its use is associated with little toxicity. The success of geftinib suggests that it is important to understand the basic mechanisms underlying lung cancer in order to evolve better therapies. The review has been prepared after conducting extensive PubMed and Medline search for related articles.

show abstract

Clinical Experience with Gefitinib in Indian Patients

Abstract: Gefitinib seems well tolerated in Indian patients with advanced NSCLC, with some clinical benefit observed.

Cited by 26 publications

References 25 publications

Optimizing patient outcome: Of equal importance in the palliative setting

Optimizing patient outcome: Of equal importance in the palliative setting

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

Geftinib

Contact Info

Product

Resources

About